A Comparative Study of Noninvasive Hypoxia Imaging with 18F-Fluoroerythronitroimidazole and 18F-Fluoromisonidazole PET/CT in Patients with Lung Cancer.

This is a clinical study to compare noninvasive hypoxia imaging using 18F-fluoroerythronitroimidazole (18F-FETNIM) and 18F-fluoromisonidazole (18F-FMISO) positron emission tomography/computed tomography (PET/CT) in patients with inoperable stages III-IV lung cancer.A total of forty-two patients with...

Full description

Bibliographic Details
Main Authors: Yuchun Wei, Wei Zhao, Yong Huang, Qingxi Yu, Shouhui Zhu, Suzhen Wang, Shuqiang Zhao, Xudong Hu, Jinming Yu, Shuanghu Yuan
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4913930?pdf=render
id doaj-3e2ae22e67a34ca08f623c886e680fa9
record_format Article
spelling doaj-3e2ae22e67a34ca08f623c886e680fa92020-11-24T22:11:40ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01116e015760610.1371/journal.pone.0157606A Comparative Study of Noninvasive Hypoxia Imaging with 18F-Fluoroerythronitroimidazole and 18F-Fluoromisonidazole PET/CT in Patients with Lung Cancer.Yuchun WeiWei ZhaoYong HuangQingxi YuShouhui ZhuSuzhen WangShuqiang ZhaoXudong HuJinming YuShuanghu YuanThis is a clinical study to compare noninvasive hypoxia imaging using 18F-fluoroerythronitroimidazole (18F-FETNIM) and 18F-fluoromisonidazole (18F-FMISO) positron emission tomography/computed tomography (PET/CT) in patients with inoperable stages III-IV lung cancer.A total of forty-two patients with inoperable stages III-IV lung cancer underwent 18F-FETNIM PET/CT (n = 18) and 18F-FMISO PET/CT (n = 24) before chemo/radiation therapy. The standard uptake values (SUVs) of malignant and normal tissues depict 18F-FETNIM PET/CT and 18F-FMISO PET/CT uptake. Tumor-to-blood ratios (T/B) were used to quantify hypoxia.All patients with lung cancer underwent 18F-FETNIM PET/CT and 18F-FMISO PET/CT successfully. Compared to 18F-FMISO, 18F-FETNIM showed similar uptake in muscle, thyroid, spleen, pancreas, heart, lung and different uptake in blood, liver, and kidney. Significantly higher SUV and T/B ratio with 18F-FMISO (2.56±0.77, 1.98±0.54), as compared to 18F-FETNIM (2.12±0.56, 1.42±0.33) were seen in tumor, P = 0.022, <0.001. For the patients with different histopathological subtypes, no significant difference of SUV (or T/B ratio) was observed both in 18F-FMISO and 18F-FETNIM in tumor. A significantly different SUV (or T/B ratio) was detected between < = 2cm, 2~5cm, and >5cm groups in 18F-FMISO PET/CT, P = 0.015 (or P = 0.029), whereas no difference was detected in 18F-FMISO PET/CT, P = 0.446 (or P = 0.707). Both 18F-FETNIM and 18F-FMISO showed significantly higher SUVs (or T/B ratios) in stage IV than stage III, P = 0.021, 0.013 (or P = 0.032, 0.02).18F-FMISO showed significantly higher uptake than 18F-FETNIM in tumor/non-tumor ratio and might be a better hypoxia tracer in lung cancer.http://europepmc.org/articles/PMC4913930?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Yuchun Wei
Wei Zhao
Yong Huang
Qingxi Yu
Shouhui Zhu
Suzhen Wang
Shuqiang Zhao
Xudong Hu
Jinming Yu
Shuanghu Yuan
spellingShingle Yuchun Wei
Wei Zhao
Yong Huang
Qingxi Yu
Shouhui Zhu
Suzhen Wang
Shuqiang Zhao
Xudong Hu
Jinming Yu
Shuanghu Yuan
A Comparative Study of Noninvasive Hypoxia Imaging with 18F-Fluoroerythronitroimidazole and 18F-Fluoromisonidazole PET/CT in Patients with Lung Cancer.
PLoS ONE
author_facet Yuchun Wei
Wei Zhao
Yong Huang
Qingxi Yu
Shouhui Zhu
Suzhen Wang
Shuqiang Zhao
Xudong Hu
Jinming Yu
Shuanghu Yuan
author_sort Yuchun Wei
title A Comparative Study of Noninvasive Hypoxia Imaging with 18F-Fluoroerythronitroimidazole and 18F-Fluoromisonidazole PET/CT in Patients with Lung Cancer.
title_short A Comparative Study of Noninvasive Hypoxia Imaging with 18F-Fluoroerythronitroimidazole and 18F-Fluoromisonidazole PET/CT in Patients with Lung Cancer.
title_full A Comparative Study of Noninvasive Hypoxia Imaging with 18F-Fluoroerythronitroimidazole and 18F-Fluoromisonidazole PET/CT in Patients with Lung Cancer.
title_fullStr A Comparative Study of Noninvasive Hypoxia Imaging with 18F-Fluoroerythronitroimidazole and 18F-Fluoromisonidazole PET/CT in Patients with Lung Cancer.
title_full_unstemmed A Comparative Study of Noninvasive Hypoxia Imaging with 18F-Fluoroerythronitroimidazole and 18F-Fluoromisonidazole PET/CT in Patients with Lung Cancer.
title_sort comparative study of noninvasive hypoxia imaging with 18f-fluoroerythronitroimidazole and 18f-fluoromisonidazole pet/ct in patients with lung cancer.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2016-01-01
description This is a clinical study to compare noninvasive hypoxia imaging using 18F-fluoroerythronitroimidazole (18F-FETNIM) and 18F-fluoromisonidazole (18F-FMISO) positron emission tomography/computed tomography (PET/CT) in patients with inoperable stages III-IV lung cancer.A total of forty-two patients with inoperable stages III-IV lung cancer underwent 18F-FETNIM PET/CT (n = 18) and 18F-FMISO PET/CT (n = 24) before chemo/radiation therapy. The standard uptake values (SUVs) of malignant and normal tissues depict 18F-FETNIM PET/CT and 18F-FMISO PET/CT uptake. Tumor-to-blood ratios (T/B) were used to quantify hypoxia.All patients with lung cancer underwent 18F-FETNIM PET/CT and 18F-FMISO PET/CT successfully. Compared to 18F-FMISO, 18F-FETNIM showed similar uptake in muscle, thyroid, spleen, pancreas, heart, lung and different uptake in blood, liver, and kidney. Significantly higher SUV and T/B ratio with 18F-FMISO (2.56±0.77, 1.98±0.54), as compared to 18F-FETNIM (2.12±0.56, 1.42±0.33) were seen in tumor, P = 0.022, <0.001. For the patients with different histopathological subtypes, no significant difference of SUV (or T/B ratio) was observed both in 18F-FMISO and 18F-FETNIM in tumor. A significantly different SUV (or T/B ratio) was detected between < = 2cm, 2~5cm, and >5cm groups in 18F-FMISO PET/CT, P = 0.015 (or P = 0.029), whereas no difference was detected in 18F-FMISO PET/CT, P = 0.446 (or P = 0.707). Both 18F-FETNIM and 18F-FMISO showed significantly higher SUVs (or T/B ratios) in stage IV than stage III, P = 0.021, 0.013 (or P = 0.032, 0.02).18F-FMISO showed significantly higher uptake than 18F-FETNIM in tumor/non-tumor ratio and might be a better hypoxia tracer in lung cancer.
url http://europepmc.org/articles/PMC4913930?pdf=render
work_keys_str_mv AT yuchunwei acomparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer
AT weizhao acomparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer
AT yonghuang acomparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer
AT qingxiyu acomparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer
AT shouhuizhu acomparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer
AT suzhenwang acomparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer
AT shuqiangzhao acomparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer
AT xudonghu acomparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer
AT jinmingyu acomparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer
AT shuanghuyuan acomparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer
AT yuchunwei comparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer
AT weizhao comparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer
AT yonghuang comparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer
AT qingxiyu comparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer
AT shouhuizhu comparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer
AT suzhenwang comparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer
AT shuqiangzhao comparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer
AT xudonghu comparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer
AT jinmingyu comparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer
AT shuanghuyuan comparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer
_version_ 1725804751360098304